Market Overview

Deutsche Bank Reiterates Buy Rating, $48 PT on Gilead Sciences on IMS Weekly Script Analysis

Share:
Related GILD
Investors Might Want To Stay Away From This Biotech ETF
Experts Talking Gilead, Not Bubbles At Detroit's Engage Conference
Hot Stocks Gilead, Alaska Air Work On New Bases (Investor's Business Daily)

In a report published Monday, Deutsche Bank reiterated its Buy rating and $48.00 price target on Gilead Sciences (NASDAQ: GILD).

Deutsche Bank noted, “Analysis of IMS Weekly scripts for week 9 of 1Q:13 (week 9 of 13) indicates that GILD's HIV franchise at $1,228.8M is tracking $66.4M better than consensus of $1,162.4M. Both Atripla &Truvada are tracking better than our projections respectively by +$22.1M & +$33.0M. Price increases were taken Jan 1 2013 on Truvada, Atripla, Complera, Viread, and Emtriva. This is additive to 1Q13 sales. Without these price increases, sales (ex-Stribild) would be tracking roughly $12.9M above consensus. Though early in launch, Stribild is tracking $21.4M better than consensus of $62.2M in 1Q13.”

Gilead Sciences closed on Friday at $45.43.

Latest Ratings for GILD

DateFirmActionFromTo
Feb 2015Credit SuisseDowngradesOutperformNeutral
Feb 2015CitigroupMaintainsBuy
Feb 2015UBSMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...